The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology

作者：Takashi Kubo, Kuniko Sunami, Takafumi Koyama, Megumi Kitami, Yasuhiro Fujiwara, Shunsuke Kondo, Kan Yonemori, Emi Noguchi, Chigusa Morizane, Yasushi Goto, Aiko Maejima, Satoru Iwasa, Tsuyoshi Hamaguchi, Akira Kawai, Kenjiro Namikawa, Ayumu Arakawa, Masanaka Sugiyama, M. Ohno, Tatsuya Yoshida, Nobuyoshi Hiraoka, Akihiko Yoshida, Miwa Yoshida, Tomohiko Nishino, Eri Furukawa, Daichi Narushima, Masaya Nagai, Mamoru Kato, Hitoshi Ichikawa, Yasuhiro Fujiwara, Takashi Kohno, Noboru Yamamoto · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.102981 · 被引用次数：14 · 研究领域：Cancer Genomics and Diagnostics、Lung Cancer Treatments and Mutations、Cancer Diagnosis and Treatment

BACKGROUND: Comprehensive genome profiling (CGP) serves as a guide for suitable genomically matched therapies for patients with cancer. However, little is known about the impact of the timing and types of cancer on the therapeutic benefit of CGP. MATERIALS AND METHODS: A single hospital-based pan-cancer prospective study (TOP-GEAR; UMIN000011141) was conducted to examine the benefit of CGP with respect to the timing and types of cancer. Patients with advanced solid tumors (>30 types) who either progressed with or without standard treatments were genotyped using a single CGP test. The subjects were followed up for a median duration of 590 days to examine therapeutic response, using progression-free survival (PFS), PFS ratio, and factors associated with therapeutic response. RESULTS: Among the 507 patients, 62 (12.2%) received matched therapies with an overall response rate (ORR) of 32.3%. The PFS ratios (≥1.3) were observed in 46.3% (19/41) of the evaluated patients. The proportion of subjects receiving such therapies in the rare cancer cohort was lower than that in the non-rare cancer cohort (9.6% and 17.4%, respectively; P = 0.010). However, ORR of the rare cancer patients was higher than that in the non-rare cancer cohort (43.8% and 20.0%, respectively; P = 0.046). Moreover, ORR of matched therapies in the first or second line after receiving the CGP test was higher than that in the third or later lines (62.5% and 21.7%, respectively; P = 0.003). Rare cancer and early-line ...